The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
|Videos|October 8, 2017
Dr. Winter Discusses Response in Follicular Lymphoma
Author(s)Jane N. Winter, MD
Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses response in follicular lymphoma.
Advertisement
Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses response in follicular lymphoma.
Follicular lymphoma is a rapidly changing field, says Winter.
Although recent evidence has shown that most patients with follicular lymphoma will do very well on therapy, about 20% will progress within the first 2 years. There is no effective way to identify this population as of now, adds Winter.
Advertisement
Related to this article
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Patients who received MBTF prior to allo-HSCT achieved promising survival outcomes and manageable safety in relapsed/refractory acute myeloid leukemia.
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.
Faculty convened for a virtual OncLive Scientific Interchange and Workshop to interpret emerging trial data and treatment strategies for systemic mastocytosis.
Advertisement
Advertisement
Trending on OncLive
1
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
2
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
Dr Borate on Efficacy Data for Shorter Venetoclax-Plus-Azacitidine Dosing in AML
5